2021-09-29-世界卫生组织-A_H7N9_-_Southern_Hemisphere_2022_3页_206kb

Antigenic and genetic analyses for avian influenza A(H7N9) candidate vaccine viruses are conducted by WHO Collaborating Centers within the Global Influenza Surveillance and Response System (GISRS). All candidate vaccine viruses mentioned have successfully passed two-way haemagglutination inhibition (HI) tests and are cleared for use under BSL-2 enhanced containment after safety evaluations.

The document details specific candidate vaccine viruses, such as CBER-RG7C*, developed through reverse genetics or synthetic methods, with origins from wild-type viruses. Institutes like the FDA's CBER, CDC, NIBSC, and others provide and manage these viruses, with contact details included for orders.

Reference antigens and potency testing reagents, including NIBRG-268 and PR8-IDCDC-RG32A, are available from sources like NIBSC and CBER/FDA, each with lot numbers for traceability. This ensures standardized testing and distribution.

Overall, the update lists multiple candidate viruses and reagents in development or preparation, facilitating global vaccine production and surveillance.